{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:40:39Z","timestamp":1793256039615,"version":"4.5.0"},"reference-count":40,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,1,15]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Resistance to immune checkpoint inhibitors and targeted treatments for cancer is common; thus, novel immunotherapy agents are needed. Urelumab is a monoclonal antibody agonist that binds to CD137 receptors expressed on T cells. Here, we report two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>CA186-018: Patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck (SCCHN) were treated in a dose-evaluation phase with urelumab 0.1\u2009mg\/kg (urelumab-0.1) every 3 weeks (Q3W)+cetuximab 250 mg\/m<jats:sup>2<\/jats:sup> (cetuximab-250) weekly; and in a dose-expansion phase with urelumab 8\u2009mg flat dose (urelumab-8) Q3W+cetuximab-250 weekly. CA186-107: The dose-escalation phase included patients with previously treated advanced solid tumors (or treated or treatment-naive melanoma); patients received urelumab 3\u2009mg flat dose (urelumab-3) or urelumab-8 every 4 weeks+nivolumab 3\u2009mg\/kg (nivolumab-3) or 240\u2009mg (nivolumab-240) every 2 weeks. In the expansion phase, patients with melanoma, non-small cell lung cancer, or SCCHN were treated with urelumab-8+nivolumab-240. Primary endpoints were safety and tolerability, and the secondary endpoint included efficacy assessments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CA186-018: 66 patients received study treatment. The most frequent treatment-related adverse events (TRAEs) were fatigue (75%; n=3) with urelumab-0.1+cetuximab-250 and dermatitis (45%; n=28) with urelumab-8+cetuximab-250. Three patients (5%) discontinued due to TRAE(s) (with urelumab-8+cetuximab-250). One patient with SCCHN had a partial response (objective response rate (ORR) 5%, with urelumab-8+cetuximab-250).<\/jats:p>\n                  <jats:p>CA186-107: 134 patients received study treatment. Fatigue was the most common TRAE (32%; n=2 with urelumab-3+nivolumab-3; n=1 with urelumab-8+nivolumab-3; n=40 with urelumab-8+nivolumab-240). Nine patients (7%) discontinued due to TRAE(s) (n=1 with urelumab-3+nivolumab-3; n=8 with urelumab-8+nivolumab-240). Patients with melanoma naive to anti-PD-1 therapy exhibited the highest ORR (49%; n=21 with urelumab-8+nivolumab-240). Intratumoral gene expression in immune-related pathways (CD3, CD8, CXCL9, GZMB) increased on treatment with urelumab+nivolumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Although the addition of urelumab at these doses was tolerable, preliminary response rates did not indicate an evident additive benefit. Nevertheless, the positive pharmacodynamics effects observed with urelumab and the high response rate in treatment-naive patients with melanoma warrant further investigation of other anti-CD137 agonist agents for treatment of cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration numbers<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02110082\">NCT02110082<\/jats:ext-link>; <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT02253992\">NCT02253992<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2023-007364","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T02:00:11Z","timestamp":1709863211000},"page":"e007364","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02110082","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02253992","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00309023","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02110082","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02253992","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3636-4143","authenticated-orcid":false,"given":"Nikhil I","family":"Khushalani","sequence":"first","affiliation":[{"name":"Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-943X","authenticated-orcid":false,"given":"Patrick A","family":"Ott","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6605-2071","authenticated-orcid":false,"given":"Robert L","family":"Ferris","sequence":"additional","affiliation":[{"name":"Hillman Cancer Center, University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, USA"},{"name":"Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Cascone","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Dermatologie, Venerologie und Allergologie, University Hospital Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung T","family":"Le","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R","family":"Sharma","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[{"name":"Aix-Marseille University, Marseille, France"},{"name":"Hopital de la Timone, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sharfman","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-4908","authenticated-orcid":false,"given":"Jason J","family":"Luke","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"CIBERONC, and Clinica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanne","family":"Lathers","sequence":"additional","affiliation":[{"name":"Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Neely","sequence":"additional","affiliation":[{"name":"Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra","family":"Suryawanshi","sequence":"additional","affiliation":[{"name":"Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abanti","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Boston Scientific, Marlborough, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Holloway","sequence":"additional","affiliation":[{"name":"Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasika","family":"Suryawanshi","sequence":"additional","affiliation":[{"name":"Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Ely","sequence":"additional","affiliation":[{"name":"Bristol Meyers Squibb Lawrenceville, Lawrenceville, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil H","family":"Segal","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2025100306522660000_12.3.e007364.1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"2025100306522660000_12.3.e007364.2","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/cas.14354","article-title":"CD137, an attractive candidate for the immunotherapy of lung cancer","volume":"111","author":"Ye","year":"2020","journal-title":"Cancer Sci"},{"key":"2025100306522660000_12.3.e007364.3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690112","article-title":"Cancer immunotherapies: from efficacy to resistance mechanisms - not only checkpoint matters","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"2025100306522660000_12.3.e007364.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.01.002"},{"key":"2025100306522660000_12.3.e007364.5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1312"},{"key":"2025100306522660000_12.3.e007364.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.2003.01217.x"},{"key":"2025100306522660000_12.3.e007364.7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4262"},{"key":"2025100306522660000_12.3.e007364.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1358"},{"key":"2025100306522660000_12.3.e007364.9","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830231037"},{"key":"2025100306522660000_12.3.e007364.10","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1998.1396"},{"key":"2025100306522660000_12.3.e007364.11","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250227"},{"key":"2025100306522660000_12.3.e007364.12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4049\/jimmunol.158.2.551","article-title":"Costimulation of CD28- T lymphocytes by 4-1BB ligand","volume":"158","author":"DeBenedette","year":"1997","journal-title":"J Immunol"},{"key":"2025100306522660000_12.3.e007364.13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0800459"},{"key":"2025100306522660000_12.3.e007364.14","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.1.47"},{"key":"2025100306522660000_12.3.e007364.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-27613-w","article-title":"CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation","volume":"12","author":"Otano","year":"2021","journal-title":"Nat Commun"},{"key":"2025100306522660000_12.3.e007364.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0879"},{"key":"2025100306522660000_12.3.e007364.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060031","article-title":"Co-stimulation through 4-1BB\/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy","volume":"8","author":"Chacon","year":"2013","journal-title":"PLoS One"},{"key":"2025100306522660000_12.3.e007364.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1272"},{"key":"2025100306522660000_12.3.e007364.19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00800","article-title":"Rethink of EGFR in cancer with Its kinase independent function on board","volume":"9","author":"Thomas","year":"2019","journal-title":"Front Oncol"},{"key":"2025100306522660000_12.3.e007364.20","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1680"},{"key":"2025100306522660000_12.3.e007364.21","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of cancer resistance to immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol"},{"key":"2025100306522660000_12.3.e007364.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3510"},{"key":"2025100306522660000_12.3.e007364.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"2025100306522660000_12.3.e007364.24","unstructured":"Eli Lilly and Company . ERBITUX\u00ae (Cetuximab). package insert; 2021. Available: https:\/\/uspl.lilly.com\/erbitux\/erbitux.html#pi [Accessed 5 Feb 2024]."},{"key":"2025100306522660000_12.3.e007364.25","unstructured":"Bristol Myers Squibb . OPDIVO\u00ae (Nivolumab) [package insert]. 2023. Available: https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf [Accessed 01 Jun 2023]."},{"key":"2025100306522660000_12.3.e007364.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"2025100306522660000_12.3.e007364.27","first-page":"429","article-title":"Rechallenge with checkpoint inhibitors in metastatic melanoma","volume":"18","author":"Reschke","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"2025100306522660000_12.3.e007364.28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1159\/000485404","article-title":"Cetuximab enhanced the cytotoxic activity of immune cells during treatment of colorectal cancer","volume":"44","author":"Wang","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"2025100306522660000_12.3.e007364.29","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13226"},{"key":"2025100306522660000_12.3.e007364.30","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.21935"},{"key":"2025100306522660000_12.3.e007364.31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1545"},{"key":"2025100306522660000_12.3.e007364.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"2025100306522660000_12.3.e007364.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1922"},{"key":"2025100306522660000_12.3.e007364.34","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000733","article-title":"New emerging targets in cancer immunotherapy: CD137\/4-1BB costimulatory axis","volume":"4","author":"Etxeberria","year":"2020","journal-title":"ESMO Open"},{"key":"2025100306522660000_12.3.e007364.35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-741041"},{"key":"2025100306522660000_12.3.e007364.36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081822","article-title":"An update on anti-CD137 antibodies in immunotherapies for cancer","volume":"20","author":"Chu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025100306522660000_12.3.e007364.37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-22-1029","article-title":"CD137 (4-1BB)-based cancer immunotherapy on Its 25th anniversary","volume":"13","author":"Melero","year":"2023","journal-title":"Cancer Discov"},{"key":"2025100306522660000_12.3.e007364.38","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2128"},{"key":"2025100306522660000_12.3.e007364.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4194"},{"key":"2025100306522660000_12.3.e007364.40","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0846-9"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:52:37Z","timestamp":1759499557000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,7]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/jitc-2023-007364"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007364","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}